{"version":"1.0","provider_name":"Times South Africa","provider_url":"https:\/\/timessouthafrica.com","author_name":"TSA","author_url":"https:\/\/timessouthafrica.com\/author\/tsa\/","title":"HPTN Studies Inform FDA\u2019s Approval of ViiV Healthcare\u2019s Long-Acting Cabotegravir Injections for HIV Prevention - Times South Africa","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"0z9SVxn8aJ\"><a href=\"https:\/\/timessouthafrica.com\/hptn-studies-inform-fdas-approval-of-viiv-healthcares-long-acting-cabotegravir-injections-for-hiv-prevention\/\">HPTN Studies Inform FDA\u2019s Approval of ViiV Healthcare\u2019s Long-Acting Cabotegravir Injections for HIV Prevention<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/timessouthafrica.com\/hptn-studies-inform-fdas-approval-of-viiv-healthcares-long-acting-cabotegravir-injections-for-hiv-prevention\/embed\/#?secret=0z9SVxn8aJ\" width=\"600\" height=\"338\" title=\"&#8220;HPTN Studies Inform FDA\u2019s Approval of ViiV Healthcare\u2019s Long-Acting Cabotegravir Injections for HIV Prevention&#8221; &#8212; Times South Africa\" data-secret=\"0z9SVxn8aJ\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) \u2014 Data from the HIV Prevention Trials Network (HPTN) studies HPTN 083 and HPTN 084 helped provide important information for yesterday\u2019s decision by the U.S. Food and Drug Administration (FDA) to approve ViiV Healthcare\u2019s long-acting cabotegravir (CAB-LA) injections for the prevention of HIV. Sponsored and co-funded by the [\u2026]"}